An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease
NCT ID: NCT00501969
Last Updated: 2014-10-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
395 participants
INTERVENTIONAL
2004-08-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
NCT00599196
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
NCT00594165
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
NCT00594386
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
NCT00505687
Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
NCT00244387
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rotigotine
Rotigotine
Rotigotine
Rotigotine trans-dermal patches once daily:
20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rotigotine
Rotigotine trans-dermal patches once daily:
20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
31 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bedford Park, , Australia
Concord, , Australia
Darlinghurst, , Australia
East Gosford, , Australia
Westmead, , Australia
Innsbruck, , Austria
Zagreb, , Croatia
Brno, , Czechia
Ostrava - Poruba, , Czechia
Pardubice, , Czechia
Pilsen, , Czechia
Prague, , Czechia
Oulu, , Finland
Pori, , Finland
Aix-en-Provence, , France
Lille, , France
Lyon, , France
Aachen, , Germany
Bochum, , Germany
Budapest, , Hungary
Miskolc, , Hungary
Pécs, , Hungary
Petah Tikva, , Israel
Tel Aviv, , Israel
Milan, , Italy
Napoli, , Italy
Padua, , Italy
Pisa, , Italy
Pozzilli, , Italy
Roma, , Italy
Auckland, , New Zealand
Christchurch, , New Zealand
Wellington, , New Zealand
Bergen, , Norway
Stavanger, , Norway
Trondheim, , Norway
Tønsberg, , Norway
Gdansk, , Poland
Krakow, , Poland
Lublin, , Poland
Mosina k/Poznania, , Poland
Olsztyn, , Poland
Warsaw, , Poland
Cape Town, , South Africa
Pretoria, , South Africa
Tygerberg, , South Africa
Barcelona, , Spain
Donostia / San Sebastian, , Spain
Madrid, , Spain
Stockholm, , Sweden
Blackpool, , United Kingdom
Glasgow, , United Kingdom
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004-000148-26
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SP0516
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.